Health and Human Services

New 340B drug rule sets drugmaker finesConsumer health groups are praising Health and Human Services’ (HHS) new rule on the Medicaid 340B drug discount program, which sets a ceiling on drug prices.
Time for renewed dialog on vaccinesWill the Trump administration promote vaccine hesitancy or create policies that are less than vaccine friendly? Or will his doubts about vaccines encourage hesitancy?
Trends in tickborne diseasesTickborne diseases are a significant health problem in the United States with over 40,000 confirmed or probable cases reported as recently as 2014. Almost 80% of these cases consist of Lyme disease, but other diseases, including viral infections, are present and have been increasing in number over the past 20 years. Experts in tickborne diseases share updates about what’s new and what’s changing in the detection and transmission of these diseases.
Judge rules: Orphan drugs not subject to 340B discountsJudge Rudolph Contreras ruled against the Department of Health and Human Services by saying that pharma companies do not have to offer rural and cancer hospitals that serve low-income populations 340B discounts on orphan drugs.
HHS, drugmaker partner on Ebola drugThe U.S. Department of Health and Human Services’ Office of the Assistant Secretary for Preparedness and Response (ASPR) and Regeneron Pharmaceuticals in Tarrytown, New York, are partnering to develop a novel Ebola virus treatment.
HHS investigates rise in genericsThe U.S. Department of Health and Human Services (HHS) will investigate how much money Medicaid has lost over the past decade paying for rising generic drug prices by comparing price increases between 2005 and 2014 against the rate of inflation.
Hitting the ACO target
Hitting the ACO targetMore than 750 government and private ACOs are now in place, helping healthcare transition away from fee-for-service. Find out what's working and what's planned for the future.
ACO model saves Medicare $384 millionAn innovative payment model created as a pilot project by the Affordable Care Act generated more than $384 million in savings for Medicare in its first two years, according to an independent evaluation report conducted by the Department of Health and Human Services (HHS).
Treatment for inhalational anthrax approvedFDA has approved Anthrax Immune Globulin Intravenous (Human) (Anthrasil, Emergent BioSolutions) also known as AIGIV, for treatment of inhalational anthrax in combination with appropriate antibacterial drugs.
HHS launches Next Generation ACO modelA new, “next generation” accountable care organization model that encourages greater coordination between providers and beneficiaries has been launched by the U.S. Department of Health and Human Services.